MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Watch List: Layoffs of 10% or More, Strategic Corporate Review, Delisting, Regulatory, Financial and/or Legal Issues
Travere Therapeutics, Inc. (NASDAQ: TVTX)*
Organization & Developments: Travere Therapeutics
Parents
Travere Therapeutics, Inc. (NASDAQ: TVTX)*
Children
2021: Regulatory Uncertainty Holding Travere Therapeutics Down Despite PROTECT Study Success
2021: Travere Therapeutics Announces Orphan Drug Designation for Sparsentan for the Treatment of IgA Nephropathy
2022: Travere Therapeutics (TVTX) Investor Presentation - Slideshow_ seekingalpha.com
2022: Travere Therapeutics: Changes In The Risk-Reward Assessment_ seekingalpha.com
2023: Travere downsizes after a failed bid for Filspari label expansion
2023: Travere's Filspari misses the mark in key trial, but market removal looks unlikely: analysts
2024: Travere Therapeutics Faces Challenges But Holds Promise With Filspari Beyond IgAN
2024: Travere Therapeutics: Cautiously Bullish Based On Improving Revenue
2024: Travere Therapeutics: Restructuring Away From Disaster
2024: Travere Therapeutics' SWOT analysis: stock poised for growth amid rare disease focus
2025: Travere Therapeutics: Establishing A Position After Last Week's Selloff
2025: Travere Therapeutics: Tricky Outlook Gives Me Pause For Thought - Downgrade
Jumps
Finance & Acquisitions: Travere Therapeutics
Key People: Travere Therapeutics